News

Cambridge-based Biogen is looking to the growth of its Alzheimer’s drug Leqembi to offset the decline of its multiple ...
( NewsNation) — New research suggests popular weight loss drugs like Ozempic and Wegovy may affect more than just fat, ...
A UK government and Eli Lilly £85 million program will expand obesity care nationwide, offering digital, community, and ...
Counterfeit drugs infiltrating the US pharma supply chain through gray market channels underscore the urgent need for ...
Novo Nordisk A/S (NYSE:NVO) is among the. Novo Nordisk A/S (NYSE:NVO) lowered its operating profit growth projections to ...
If you’re pregnant or hoping to become pregnant, it’s natural to have questions about your medications. And if you’re taking ...
Novo Nordisk's FY 2025 guidance cuts are driven by softer U.S. Wegovy/Ozempic and GLP-1 trends. Click here to find out why I ...
Corporate lobbying shop Ballard Partners previously employed Donald Trump’s chief of staff as well as his attorney general.
Novo Nordisk's steep stock decline has pushed it into deep undervaluation, now trading at attractive multiples below ...
IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN NOVO NORDISK A/S (NVO), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.
Weight-loss drugs significantly improve health, though they’re also tied to increased spending on other medical care that’s sustained over time, a new study found.